Acquisition History / Neurocrine Biosciences, Inc. / Soleno Therapeutics, Inc.
Neurocrine Biosciences, Inc. Acquires Soleno Therapeutics, Inc.
Announced April 6, 2026 — $2.90B
What happened
Soleno Therapeutics markets VYKAT XR for hyperphagia in Prader-Willi syndrome. Neurocrine agreed on April 6, 2026 to acquire it for $53.00 per share in cash, a total equity value of $2.9B, to strengthen its endocrinology and rare disease franchise.
- Acquirer
- Neurocrine Biosciences, Inc.
- Target
- Soleno Therapeutics, Inc.
- Announced
- April 6, 2026
- Price
- $2.90B
- Industry
- Rare disease pharmaceuticals
- Buyer type
- Strategic acquirer
- Status
- Announced, not yet closed
By the numbers
Frequently Asked Questions About This Acquisition
When did Neurocrine Biosciences, Inc. acquire Soleno Therapeutics, Inc.?
Neurocrine Biosciences, Inc. acquired Soleno Therapeutics, Inc. on April 6, 2026. This was Neurocrine Biosciences, Inc.'s 1st publicly tracked acquisition out of 1 we have on record.
How much did Neurocrine Biosciences, Inc. pay for Soleno Therapeutics, Inc.?
Neurocrine Biosciences, Inc. paid $2.90B for Soleno Therapeutics, Inc..
What does Soleno Therapeutics, Inc. do?
Soleno Therapeutics markets VYKAT XR for hyperphagia in Prader-Willi syndrome. Neurocrine agreed on April 6, 2026 to acquire it for $53.00 per share in cash, a total equity value of $2.9B, to strengthen its endocrinology and rare disease franchise.
What other Rare disease pharmaceuticals companies has Neurocrine Biosciences, Inc. acquired?
Soleno Therapeutics, Inc. is Neurocrine Biosciences, Inc.'s only publicly tracked acquisition in Rare disease pharmaceuticals so far.